Dexcom is a medical technology company that helps people with diabetes manage their blood sugar levels in a simple way. The company makes continuous glucose monitoring (CGM) devices, small wearable sensors that track glucose in real time so users can see their levels without constant fingerstick tests. In short, Dexcom’s innovations give people more freedom and control in managing diabetes every day.
About DexCom, Inc. (DXCM)
Dexcom (NASDAQ: DXCM) is a pioneer in continuous glucose monitoring (CGM) technology. Founded in 1999 and based in San Diego, California, the company has developed innovative devices that have transformed the way people manage diabetes. Dexcom’s CGM systems provide real-time glucose data to both patients and healthcare professionals, reducing the need for traditional blood testing.
Over time, Dexcom has grown into a global leader in diabetes technology, employing thousands of people worldwide and serving customers in more than 50 countries. Dexcom is also a publicly traded company and a component of the S&P 500 index.
Vision and Mission of DexCom, Inc.
Dexcom’s mission is to empower people to take control of diabetes through innovative technology. This means the company is dedicated to making diabetes management easier by giving patients tools to monitor their glucose so they can live life to the fullest. The vision is a world where managing diabetes is less of a burden, and Dexcom envisions simpler and more accessible diabetes care for everyone.
They focus on listening to the needs of users, caregivers, and healthcare providers to continuously improve their products and services. This patient-centric approach is reflected in Dexcom’s core values of listening, serving with integrity, thinking big, and being dependable, all aimed at improving quality of life for people with diabetes.
Products of DexCom, Inc.
Dexcom’s product lineup centers around its innovative continuous glucose monitoring systems, which are designed to provide real-time glucose readings through wearable sensors that transmit data directly to a user’s smartphone or compatible device. These devices have revolutionized diabetes care, allowing users to easily monitor glucose trends, receive alerts, and manage their health more proactively, all without the need for routine fingerstick tests.
One of Dexcom’s most notable products is the Dexcom G6, launched in 2018. This system introduced a new level of convenience and accuracy by offering real-time readings and eliminating the need for fingerstick calibrations. With sensors that last up to 10 days, the G6 quickly became a favorite among users.
Building on that success, the Dexcom G7 was introduced in late 2022. It features a more compact design, a shorter warm-up period of just 30 minutes, and integrates the sensor and transmitter into a single unit, making it even easier and more comfortable to use.
For users seeking a more affordable option, Dexcom developed Dexcom ONE, a simplified version of its CGM technology aimed at expanding accessibility in various international markets. While more cost-effective, it still delivers the core benefits of continuous glucose monitoring.
In 2024, Dexcom broke new ground with the launch of Dexcom Stelo, the first over-the-counter CGM approved in the U.S. Designed specifically for people with Type 2 diabetes or pre-diabetes who are not on insulin, Stelo opens the door for more individuals to gain insights into their glucose levels and make informed lifestyle choices without a prescription.
Key Figures at DexCom, Inc.
DexCom, Inc. has been led and shaped by several key leaders who have contributed to the growth and development of the institution. Their expertise and strategic vision have played a crucial role in strengthening Wells Fargo’s global position.
- Charles W. Scharf, as CEO, has led Wells Fargo through a major transformation, focusing on operational efficiency, regulatory compliance, and customer-centric innovation. Under his leadership, the bank has reinforced its commitment to transparency and financial stability.
- Steven D. Black, as Chairman of the Board, provides strategic oversight and ensures that Wells Fargo aligns with long-term growth and risk management objectives. His extensive experience in financial services strengthens the bank’s governance framework.
- Michael P. Santomassimo, as CFO, has played a crucial role in restructuring Wells Fargo’s financial strategies, ensuring sustainable profitability and strong capital management in a competitive banking environment.
Stock Price Fluctuations of DexCom, Inc.
Dexcom’s stock (NASDAQ: DXCM) has experienced steady growth over the years, reflecting the company’s strong performance and leadership in diabetes technology. In June 2022, the company executed a four-for-one stock split, a move that made its shares more accessible to a broader range of investors. Dexcom has consistently demonstrated solid financial performance, including a 27% year-over-year revenue increase in a recent quarter.
In addition to strong earnings, Dexcom’s inclusion in major indices like the Nasdaq-100 and S&P 500 highlights its status as a key player in the healthcare and tech sectors. While the stock can be subject to market fluctuations, many investors view Dexcom as a promising long-term opportunity, particularly given the rising global demand for advanced diabetes management solutions.
History and Evolution of Deutsche Bank AG
Dexcom’s story began in 1999, when it was founded in San Diego, California, with a bold mission to transform diabetes care through technology. In 2006, the company launched its first continuous glucose monitoring system, the Dexcom STS, which marked the start of a new era in real-time glucose tracking. Just a year later, the Dexcom Seven CGM was introduced, allowing for longer sensor wear and enhancing user convenience.
The innovation continued in 2012 with the release of the G4 Platinum CGM, kicking off the “G series” with improved accuracy and user-friendly features. By 2015, Dexcom pushed boundaries again by launching the G5 Mobile, the first CGM capable of transmitting glucose data directly to smartphones, eliminating the need for separate receivers. In 2018, the company rolled out the Dexcom G6, a game-changing device that required no fingerstick calibration and featured a 10-day sensor life.
As the company grew, so did its recognition. In 2020, Dexcom was added to the Nasdaq-100 index, a milestone reflecting its rising influence in both healthcare and technology sectors. Then in 2022, the G7 CGM system received approval, setting new standards with its compact design and unmatched accuracy.
The journey reached another significant point in 2024 with the launch of Dexcom Stelo, the first over-the-counter, FDA-cleared CGM in the United States. This breakthrough made glucose monitoring more accessible, especially for individuals with Type 2 diabetes or pre-diabetes who are not on insulin.
From a small startup to a globally recognized leader in diabetes technology, Dexcom has consistently delivered innovation with a deep commitment to empowering people through smart, user-focused solutions.
How to Buy DexCom, Inc. (DXCM) Stocks
Interested in buying shares of this tech company? You can buy DexCom, Inc. (DXCM) shares with simple steps:
- Install Nanovest app on the App Store or Play Store.
- Register according to the instructions.
- Verify your identity for security and convenience when buying stocks through the KYC feature which you can do in just 1 minute.
- Top Up your balance to your Nanovest account.
- Go to the stock menu, search and select DexCom, Inc. (DXCM)
- Click the Buy button and confirm the purchase with your desired amount. You can start with only IDR 5,000.
Before investing in the stocks you want, do some research and analysis first. You can do this by checking company profile, industry conditions, company financial reports, and analyzing previous stock price movements. This analysis is important so that you can develop an accurate investment strategy and minimize losses.
Is it Safe to Buy DexCom, Inc. (DXCM) Stocks on Nanovest?
Of course. Nanovest is supported by a number of professional partners who have a good reputation in providing their services. One of them is supported by S-Quantum Engine technology by Sinarmas Financial Services.
For global and US stocks, Nanovest partners with brokers registered with the United Stated Financial Industry Regulatory Authority (FINRA) – which insures brokerage accounts held by Nanovest users up to U$S 500k by the United States Securities Investor Protection Corporation (SIPC).
For crypto assets, Nanovest is registered with the Commodity Futures Trading Supervisory Agency (Bappebti). The Nanovest platform itself has also been insured through a partnership with Sinarmas Insurance.
Disclaimer
All content on this website is for informational purposes and doesn’t constitute a recommendation to buy/sell any stock or digital asset. Investors should understand the nature of stocks and digital assets, including return and risk requirements of the assets. We encourage investors to fully understand the assets and risks before making any investment. Always do your own research.
See More Stocks
- Netflix, Inc. (NFLX) Stocks
- Meta Platforms, Inc. (META) Stocks
- Alphabet Inc. Class C (GOOG) Stocks
- Spotify Technology SA (SPOT) Stocks
- Amazon.com, Inc. (AMZN) Stocks
- Intel Corporation (INTC) Stocks
- Apple Inc. (AAPL) Stocks
- Microsoft Corporation (MSFT) Stocks
- Tesla, Inc. (TSLA) Stocks
- Alibaba Group (BABA) Stocks
- Visa Inc. (V) Stocks
- Citigroup Inc. (C) Stocks
- JPMorgan Chase & Co (JPM) Stocks
- HSBC Holdings plc (HSBC) Stocks
- Chevron Corporation (CVX) Stocks
- General Motors Co (GM) Stocks
News & Articles
